THE WIRE · № 79641
Vector Science & Therapeutics Corp. Appoints Russell Starr as President
01 THE MACHINE READ
WHY IT MATTERS.
A capital-markets executive joining a small TSXV biotech signals a possible strategic or financing shift, but details are thin.
Small-cap leadership change hints at capital strategy
Financing or partnership announcements
Micro-cap, limited liquidity and disclosure
FULL DISPATCH
Capital markets executive and long-time Company stakeholder joins senior leadership to help drive Vector's next phase of growth TORONTO, Oct. 14, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) (the "Company") today announced the appointment of Russell Starr as...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence2026-10-14 11:36 UTC
New Survey: 76% of People Say Health Care Is A Top Three Issue Determining Their Vote2026-10-14 12:09 UTC
Senior Star Marks 50 Years and Earns FORTUNE Best Workplace Recognition2026-10-14 12:10 UTC
ROMTech Wins Newsweek 2026 AI Impact Health Award for AI-Enabled Remote Patient Monitoring2026-10-14 12:17 UTC
NYC & Global Walk - 2026 FINAL Walk with Us to Cure Lupus Returns to New York City and Around the World on October 242026-10-14 12:28 UTC
J&J raises its forecast again. CFO Joe Wolk on what's driving it2026-10-13 21:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.